肾小球疾病：FSGS。
Glomerular diseases: FSGS.
机构信息
Division of Nephrology, University Health Network, University of Toronto, Toronto, Canada.
出版信息
Clin J Am Soc Nephrol. 2014 Mar;9(3):626-32. doi: 10.2215/CJN.05810513. Epub 2013 Aug 29.
Abstract
FSGS is a lesion, not a disease. The separation into primary FSGS (a result of immunologic-mediated injury) versus secondary FSGS (related to a variety of causes) is often difficult. Even when this particular issue is carefully evaluated, the therapeutic implications are not always apparent. Newer literature on both biomarker discovery and on the genetic basis of FSGS is reviewed in this context. In addition, the thorny implications of obesity as it relates to the FSGS lesion are discussed. An overall practical algorithmic approach to the management and treatment of the FSGS lesion that integrates these controversial overlap areas is suggested.
摘要
FSGS 是一种病变，而不是一种疾病。原发性 FSGS（由免疫介导损伤引起）与继发性 FSGS（与多种原因相关）的区分通常较为困难。即使仔细评估了这个特定问题，治疗的意义也并不总是很明显。本文在这一背景下回顾了有关 FSGS 的生物标志物发现和遗传基础的最新文献。此外，还讨论了肥胖与 FSGS 病变之间的复杂关系。本文提出了一种整体实用的算法方法，用于管理和治疗 FSGS 病变，该方法整合了这些有争议的重叠领域。
相似文献
1
Glomerular diseases: FSGS.肾小球疾病：FSGS。
Clin J Am Soc Nephrol. 2014 Mar;9(3):626-32. doi: 10.2215/CJN.05810513. Epub 2013 Aug 29.
2
Advanced therapeutics in focal and segmental glomerulosclerosis.局灶节段性肾小球硬化的先进治疗方法
Nephrology (Carlton). 2018 Oct;23 Suppl 4:57-61. doi: 10.1111/nep.13463.
3
Focal segmental glomerulosclerosis plays a major role in the progression of IgA nephropathy. II. Light microscopic and clinical studies.局灶节段性肾小球硬化在 IgA 肾病的进展中起着重要作用。二、光镜和临床研究。
Kidney Int. 2011 Mar;79(6):643-654. doi: 10.1038/ki.2010.460. Epub 2010 Dec 22.
4
Podocin and uPAR are good biomarkers in cases of Focal and segmental glomerulosclerosis in pediatric renal biopsies.足细胞和尿激酶型纤溶酶原激活物受体(uPAR)是儿童肾活检局灶节段性肾小球硬化的良好生物标志物。
PLoS One. 2019 Jun 12;14(6):e0217569. doi: 10.1371/journal.pone.0217569. eCollection 2019.
5
Focal Segmental Glomerulosclerosis: State-of-the-Art and Clinical Perspective.局灶节段性肾小球硬化症：现状与临床视角。
Nephron. 2020;144(9):413-427. doi: 10.1159/000508099. Epub 2020 Jul 28.
6
Collapsing Lesions and Focal Segmental Glomerulosclerosis in Pregnancy: A Report of 3 Cases.妊娠相关性塌陷性病变和局灶节段性肾小球硬化症：3 例报告
Am J Kidney Dis. 2019 Dec;74(6):837-843. doi: 10.1053/j.ajkd.2019.04.026. Epub 2019 Aug 1.
7
Glomerular C4d deposition can precede the development of focal segmental glomerulosclerosis.肾小球 C4d 沉积可先于局灶节段性肾小球硬化症的发生。
Kidney Int. 2019 Sep;96(3):738-749. doi: 10.1016/j.kint.2019.04.028. Epub 2019 May 16.
8
Glomerular growth in childhood focal segmental glomerulosclerosis.儿童局灶节段性肾小球硬化症中的肾小球生长
Pediatr Nephrol. 1998 Feb;12(2):108-12. doi: 10.1007/s004670050415.
9
Genetic studies of focal segmental glomerulosclerosis: a waste of scientific time?局灶节段性肾小球硬化症的遗传学研究：浪费科学时间？
Pediatr Nephrol. 2020 Jan;35(1):9-16. doi: 10.1007/s00467-018-4161-6. Epub 2018 Dec 27.
10
Histomorphological classification of focal segmental glomerulosclerosis: a critical evaluation of clinical, histologic and morphometric features.局灶节段性肾小球硬化的组织形态学分类：对临床、组织学和形态测量学特征的批判性评估
Saudi J Kidney Dis Transpl. 2012 Sep;23(5):1008-16. doi: 10.4103/1319-2442.100883.
引用本文的文献
1
Patients With Mild ADPKD by Kidney Imaging but Low Estimated GFR.经肾脏影像学检查诊断为轻度常染色体显性多囊肾病但估算肾小球滤过率较低的患者。
Kidney Int Rep. 2025 Apr 3;10(6):1855-1863. doi: 10.1016/j.ekir.2025.03.045. eCollection 2025 Jun.
2
Clinical relevance of computationally derived tubular features and their spatial relationships with the interstitial microenvironment in minimal change disease/focal segmental glomerulosclerosis.微小病变病/局灶节段性肾小球硬化中通过计算得出的肾小管特征及其与间质微环境的空间关系的临床相关性。
Kidney Int. 2025 Aug;108(2):293-309. doi: 10.1016/j.kint.2025.04.026. Epub 2025 May 21.
3
Podocytes in health and glomerular disease.健康与肾小球疾病中的足细胞。
Front Cell Dev Biol. 2025 Apr 24;13:1564847. doi: 10.3389/fcell.2025.1564847. eCollection 2025.
4
Advances in focal segmental glomerulosclerosis research: genetic causes to non-coding RNAs.局灶节段性肾小球硬化症研究进展：从遗传病因到非编码RNA
Mol Biol Rep. 2025 Apr 10;52(1):384. doi: 10.1007/s11033-025-10488-1.
5
Targeting endoplasmic reticulum stress: an innovative therapeutic strategy for podocyte-related kidney diseases.靶向内质网应激：一种治疗足细胞相关肾脏疾病的创新策略。
J Transl Med. 2025 Jan 21;23(1):95. doi: 10.1186/s12967-025-06076-3.
6
Targeting the Type I Interferon Pathway in Glomerular Kidney Disease: Rationale and Therapeutic Opportunities.靶向肾小球肾病中的I型干扰素通路：原理与治疗机会
Kidney Int Rep. 2024 Oct 21;10(1):29-39. doi: 10.1016/j.ekir.2024.10.013. eCollection 2025 Jan.
7
Precision Medicine Proof-of-Concept Study of a TNF Inhibitor in FSGS and Treatment-Resistant Minimal Change Disease.肿瘤坏死因子抑制剂治疗局灶节段性肾小球硬化症和难治性微小病变肾病的精准医学概念验证研究
Kidney360. 2025 Feb 1;6(2):284-295. doi: 10.34067/KID.0000000635. Epub 2024 Nov 18.
8
Oxidative stress and senescence in aging kidneys: the protective role of SIRT1.衰老肾脏中的氧化应激与衰老：SIRT1的保护作用
EXCLI J. 2024 Aug 27;23:1030-1067. doi: 10.17179/excli2024-7519. eCollection 2024.
9
Anuria after kidney transplantation diagnosed as early recurrence of focal segmental glomerulosclerosis combined with acute calcineurin inhibitor nephrotoxicity: a case report and literature review.肾移植后发生无尿，诊断为局灶节段性肾小球硬化症早期复发合并急性钙调磷酸酶抑制剂肾毒性：病例报告及文献复习。
BMC Nephrol. 2024 Apr 5;25(1):123. doi: 10.1186/s12882-024-03524-y.
10
The most common founder pathogenic variant c.868G > A (p.Val290Met) in the gene in a representative adult Czech cohort with focal segmental glomerulosclerosis is associated with a milder disease and its underdiagnosis in childhood.在一个患有局灶节段性肾小球硬化的代表性捷克成年队列中，该基因最常见的奠基者致病性变异c.868G > A（p.Val290Met）与较轻的疾病及其在儿童期的诊断不足有关。
Front Med (Lausanne). 2023 Dec 19;10:1320054. doi: 10.3389/fmed.2023.1320054. eCollection 2023.
本文引用的文献
1
Plasma soluble urokinase receptor levels are increased but do not distinguish primary from secondary focal segmental glomerulosclerosis.血浆可溶性尿激酶受体水平升高，但不能区分原发性和继发性局灶节段性肾小球硬化症。
Kidney Int. 2013 Aug;84(2):366-72. doi: 10.1038/ki.2013.55. Epub 2013 Feb 27.
2
Circulating suPAR in two cohorts of primary FSGS.原发性 FSGS 两队列的循环 suPAR。
J Am Soc Nephrol. 2012 Dec;23(12):2051-9. doi: 10.1681/ASN.2012030302. Epub 2012 Nov 8.
3
The KDIGO practice guideline on glomerulonephritis: reading between the (guide)lines--application to the individual patient.KDIGO 肾小球肾炎实践指南：从（指南）字里行间看问题——针对个体患者的应用。
Kidney Int. 2012 Oct;82(8):840-56. doi: 10.1038/ki.2012.280. Epub 2012 Aug 15.
4
Apolipoprotein L1 gene variants associate with hypertension-attributed nephropathy and the rate of kidney function decline in African Americans.载脂蛋白 L1 基因变异与非裔美国人的高血压相关肾病及肾功能下降速度相关。
Kidney Int. 2013 Jan;83(1):114-20. doi: 10.1038/ki.2012.263. Epub 2012 Jul 25.
5
Usefulness of suPAR as a biological marker in patients with systemic inflammation or infection: a systematic review.suPAR 作为全身炎症或感染患者的生物标志物的效用：系统评价。
Intensive Care Med. 2012 Sep;38(9):1418-28. doi: 10.1007/s00134-012-2613-1. Epub 2012 Jun 16.
6
Genetic causes of focal segmental glomerulosclerosis: implications for clinical practice.局灶节段性肾小球硬化症的遗传学病因：对临床实践的影响。
Nephrol Dial Transplant. 2012 Mar;27(3):882-90. doi: 10.1093/ndt/gfr771. Epub 2012 Feb 14.
7
Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis.循环尿激酶受体是局灶节段性肾小球硬化的病因。
Nat Med. 2011 Jul 31;17(8):952-60. doi: 10.1038/nm.2411.
8
Clinical trial of focal segmental glomerulosclerosis in children and young adults.儿童及青年局灶节段性肾小球硬化症的临床试验。
Kidney Int. 2011 Oct;80(8):868-78. doi: 10.1038/ki.2011.195. Epub 2011 Jul 6.
9
Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis.利妥昔单抗靶向复发性局灶节段性肾小球硬化的足细胞。
Sci Transl Med. 2011 Jun 1;3(85):85ra46. doi: 10.1126/scitranslmed.3002231.
10
Circulating soluble urokinase plasminogen activator receptor is stably elevated during the first week of treatment in the intensive care unit and predicts mortality in critically ill patients.循环可溶性尿激酶型纤溶酶原激活物受体在重症监护病房治疗的第一周内稳定升高，并可预测危重症患者的死亡率。
Crit Care. 2011;15(1):R63. doi: 10.1186/cc10037. Epub 2011 Feb 16.
Zotero 插件